Asia Pacific Alzheimer Diagnosis and Treatment Market Size

Asia Pacific Alzheimer's Diagnosis and Treatment Market size is expected to cross USD 7,034.3 Million by the end of 2033, growing at a CAGR of 14.6% during the forecast period, i.e., 2023-2033. In the year 2022, the industry size of asia pacific alzheimer’s diagnosis and treatment was USD 1,686.9 Million. The growth of the market can be attributed to the growing count of Alzheimer’s patients. There are more than 4 million dementia sufferers in India. Furthermore, the count is further expected to increase and reach nearly 11 million by 2050. There is various variable that imposes the risk of developing dementia. The factors include smoking, obesity, excessive blood sugar, and lack of subject knowledge. Although, the significant rise of 197% in dementia cases is attributed to the growing ageing population.

In addition to these, factors that are believed to fuel the market growth of Asia Pacific Alzheimer’s diagnosis and treatment include rise in the number of clinical trials being carried out on various drugs, and higher approvals of the drugs. For instance, the U.S. Food and Drug Administration has given lecanemab, an experimental anti-amyloid beta (A) protofibril antibody for the treatment of early Alzheimer's disease (AD), Fast Track designation, the drugs were developed by the combined effort of Eisai Co., Ltd. and Biogen Inc. Furthermore, the market growth can also be attributed to the rising efforts to boost the hospital and clinic services for the patients suffering from dementia. BMC-regulated KEM Hospital inaugurated the very first free clinic in Mumbai, India for patient with dementia.